Synthesis and in vitro antiprotozoal activity of some 2- amino-4-phenyloxazole derivatives by Carballo, Rubén M. et al.
Carballo et al 
Trop J Pharm Res, August 2017; 16(8): 1951  
 
Tropical Journal of Pharmaceutical Research August 2017; 16 (8): 1951-1956 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v16i8.27 
Original Research Article 
 
 
Synthesis and in vitro antiprotozoal activity of some 2-
amino-4-phenyloxazole derivatives 
 
Rubén M Carballo1, Jesús Patrón-Vázquez1, David Cáceres-Castillo1, Ramiro 
Quijano-Quiñones1, Angel Herrera-España1, Rosa E Moo-Puc2, Juan Chalé-
Dzul2 and Gonzalo J Mena-Rejón1* 
1Facultad de Química, Universidad Autónoma de Yucatán, C. 43 No. 613 x 90 Col. Inalámbrica, C.P. 97069, Mérida, Yucatán, 
México. 2Unidad de Investigación Médica Yucatán, Unidad Médica de Alta Especialidad, Centro Médico “Ignacio García 
Téllez”, IMSS, C. 41 No.439 Col. Industrial, C.P. 97150, Mérida, Yucatán, México 
 
*For correspondence: Email: mrejon@uady.mx; Tel.: +52 99 9225711 
 
Sent for review: 10 March 2017        Revised accepted: 20 July 2017 
 
Abstract 
Purpose: To prepare some 2-amino-4-(p-substituted phenyl)-oxazole derivatives and to evaluate their 
in vitro antiprotozoal activity against Giardia lamblia and Trichomonas vaginalis. 
Methods: The 2-amino-4-(p-substituted phenyl)-oxazoles (a-g) were synthesized by microwave (MW) 
irradiation of mixtures of p-substituted 2-bromoacetophenones and urea in dimethylformamide (DMF). 
All compounds were identified by 1H and 13C nuclear magnetic resonance (NMR) spectroscopy and low- 
and high-resolution mass spectrometry (HRMS). NMR assignments were made based on heteronuclear 
single quantum coherence (HSQC) and heteronuclear multiple bond correlation (HMBC) experiments. 
Each synthesized compound’s melting point was determined.  Antiprotozoal activity against Giardia 
intestinalis and Trichomonas vaginalis was quantified using a rigorous and sensitive subculture method. 
The commercial drug, metronidazole, was used as positive control. The 50 % inhibitory concentration 
(IC50) of the antiprotozoal agents for each protozoa was determined. 
Results: Seven 2-amino-4-(p-substituted phenyl)-oxazoles (a-g) were synthesized. The most active 
compounds against G. lamblia was 2-amino-4-(p-benzoyloxyphenyl)-oxazole (3d) with an IC50 of 1.17 
µM, while compound 3e (2-amino-4-(p-bromophenyl)-oxazole) showed the highest anti-trichomonal 
activity (IC50, 1.89 µM). 
Conclusion: The in vitro antigiardial activity of 2-amino-4-(p-benzoyloxyphenyl) oxazole was higher 
than that exhibited by metronidazole; however, it is necessary increase the number of synthetic 
derivatives in order to be able to determine their structure-activity relationship. 
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Giardiasis is an intestinal infection in humans by 
Giardia lamblia (syn. Giardia intestinalis, Giardia 
duodenalis), a cosmopolitan anaerobic 
gastrointestinal protozoan. Approximately one 
billion people worldwide have giardiasis, and an 
estimated 280 million cases occur annually, 
leading to 2.5 million deaths [1]. Giardia lamblia 
exhibits high prevalence in a variety of domestic, 
livestock and wild animals [2]. 
 
The colonization of the human small intestine by 
G. lamblia causes diarrhea, epigastric pain, 
nausea, vomiting, cramps, and weight loss [3]. 
Chronic giardiasis leads to malabsorption 
syndrome associated malnutrition, including 
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failure-to-thrive in children. Reported long-term 
clinical sequelae include significant reductions in 
height and IQ in children aged 7 - 9 years who 
had suffered multiple episodes of chronic 
diarrhea, lasting more than two weeks, during the 
first 24 months of life [4]. 
 
The most common sexually-transmitted disease 
in the world is trichomoniasis, caused by the 
amitochondriate protozoan parasite Trichomonas 
vaginalis. Disease incidence is estimated at 276 
million new cases a year [5]. This protozoan 
pathogen mainly affects the squamous 
epithelium of human female and male urogenital 
tracts. Infection by T. vaginalis in women leads to 
vaginal discharge and edema, vulvar itching, 
erythema, infertility, and can affect pregnancy 
course, causing premature birth or low birth 
weight. In men, it causes dysuria, epididymitis, 
urethritis, and prostatitis [6,7]. Trichonomiasis 
has also been associated with a predisposition to 
cervical and prostate cancers, and increased 
risks of HIV and HPV acquisition and 
transmission [8]. 
 
Although giardiasis and trichomoniasis are 
significant worldwide public health issues, 
research into their pharmaceutical treatment has 
been slow [9, 10]. The most commonly used 
antigiardiasic drugs are 5-nitroimidazoles, 
metronidazole, tinidazole, secnidazole, and 
ornidazole [11]; while only metronidazole and 
tinidazole are recommended for treating T. 
vaginalis infections [8]. Most of the drugs 
currently used to treat these diseases were 
developed decades ago and produces side 
effects such headache, vertigo, nausea, allergic 
reactions, and in some cases neurotoxicity. In 
addition reports exist of metronidazole-resistant 
G. lamblia and T. vaginalis strains [11]. 
 
Our research into antiprotozoal compounds has 
recently focused on the antiprotozoal activity of 
five-membered heterocyclic systems. 
Aryloxazole derivatives are reported to have 
significant antiprotozoal activities (IC50 from 0.07 
to > 5 µg/mL) [12]. In a previous paper we 
reported on the synthesis of several 2-amino-4-
arylthiazole and evaluation of their in vitro anti-
giardiasic activity with encouraging results [13]. 
Based on these findings, we synthesized seven 
2-amino-4-(p-substituted-phenyl)-1,3-oxazoles, 
and evaluated their antiprotozoal activity in vitro 







Starting materials and reagents were purchased 
from Sigma-Aldrich and used without further 
purification. All solvents were reagent grade. 
Microwave irradiations were done in a CEM 
Discover microwave reactor in standard open 
vessels. Temperature was monitored during the 
reaction with the IR pyrometer of the microwave 
reactor. Analytical thin-layer chromatography 
(TLC) was done using a 25 μm particle size and 
a 60 Å pore diameter silica gel matrix (containing 
a fluorescent indicator at 254 nm) (Sigma-
Aldrich). Compounds were viewed using 
ultraviolet light. Flash chromatography was done 
using Sigma-Aldrich silica gel (0.002 - 0.025 mm 
particle size). Melting points were determined on 
an Electrothermal IA9100 apparatus in open 
capillaries. Low- and high-resolution mass 
spectra (MS) were obtained on a Jeol GC-Mate II 
under electron impact (EI) at 70 eV. 1H and 13C 
spectra at 400.1 and 100.6 MHz, respectively, as 
well as 2D homonuclear and heteronuclear 
experiments were performed on a Bruker 
DPX400 Avance spectrometer. Chemical shifts 
were registered in ppm (δ) using the residual 
solvent signal (DMSO-d6) as internal reference. 
The synthesis route of the title compounds (3a-
3g) is shown in Figure 1. 
 
Procedure for synthesis of 2-amino-4-(p-
phenylsubstituted)oxazoles (3a-g) 
 
A mixture of p-substituted 2-bromoacetophenone 
(1a-g) (5 mmol) and urea (2) (35 mmol) in DMF 
(1 mL) was subjected to MW irradiation (35 W) at 
138 °C for 20 min (Figure 1). 
 
 
Figure 1: Synthesis of 2-amino-4-aryloxazoles 
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After completion of the reaction the solvent was 
removed at reduced pressure. The final product 
was purified by flash column chromatography 
using hexane:ethyl acetate (mixtures of 
increasing polarity) as eluent to yield 2-amino-4-
aryloxazoles 3a-g. 
 
In vitro giardicidal and trichomonicidal assay 
 
G. lamblia strain IMSS:0696:1 was cultured in 
TYI-S-33 modified medium, supplemented with 
10 % calf serum and bovine bile, and T. vaginalis 
strain GT3 was cultured in TYI-S-33 medium, 
supplemented with 10 % bovine serum. For the 
bioassay, the compounds were dissolved in 1 mL 
of dimethylsulfoxide (DMSO) and added to 
microtubes containing 1.5 mL of medium to 
reach concentrations of 1, 2, 10, and 20 µg/mL. 
The solutions were inoculated with G. lamblia or 
T. vaginalis to achieve an inoculum of 4 × 104 
trophozoites/mL and then incubated for 24 h (T. 
vaginalis) or 48 h (G. lamblia) at 37 ºC. Each test 
included metronidazole as positive control and 
trophozoites incubated in culture medium with 
DMSO used in the experiments as the negative 
control. After the incubation, trophozoites were 
washed and sub-cultured for another 48 h in 
fresh medium alone. At the end of this period, 
trophozoites were counted using a 
haemocytometer and the 50 % inhibitory 




All the quantum chemical and descriptor 
calculations for each synthesized compound (3a-
g) were performed with the Spartan10 code. 
Pople’s 6-31+G(d,p) basis set was used along 
the B3LYP functional. Frequency calculations 
were performed to characterize all the stationary 
points at the same computational level. The 
minimum structures were identified from the 




The compound concentration that inhibited 50 % 
of trophozoite growth (IC50) was calculated by 
dose-response (variable slope) technique. All 
concentrations were evaluated in duplicate and 
each assay run in triplicate. All statistical 
analyses were performed using GraphPad Prism 




All compounds were identified by 1H and 13C 
NMR spectroscopy and low and high resolution 
mass spectrometry. The NMR assignments were 
based on HSQC and HMBC experiments, and all 
data were in full agreement with the assigned 
structures. The spectroscopic data of title 




White amorphous solid; yield: 29 %; m. p. 137 - 
139 °C; 1H NMR (400 MHz, DMSO-d6): δ 7.87 (s, 
1H), 7.63 (d, J = 7.8 Hz, 2H), 7.35 (t, J = 7.6 Hz, 
2H), 7.23 (t, J = 7.3 Hz, 1H), 6.74 (s, 2H); 13C 
NMR (100 MHz, DMSO-d6): δ 161.7, 139.1, 
132.1, 128.6, 127.4, 127.3, 124.8.; EIMS (m/z): 
160 (93), 131 (12), 104 (100), 89 (19), 77 (15), 
63 (7), 51 (6); HREIMS: C9H8N2O, calcd.: 




White amorphous solid; yield: 21 %; m. p. 159 - 
161 °C; 1H NMR (400 MHz, DMSO-d6): δ 7.81 (s, 
1H), 7.52 (d, J = 8.0 Hz, 2H), 7.16 (d, J = 7.9 Hz, 
2H), 6.71 (s, 2H), 2.29 (s, 3H); 13C NMR (100 
MHz, DMSO-d6): δ 161.5, 139.0, 136.4, 129.3, 
129.1, 126.8, 124.7, 20.9; EIMS (m/z): 174 (82), 
145 (10), 118 (100), 103 (11), 91 (8), 77 (8), 65 
(4), 51 (4); HREIMS: C10H10N2O, calcd.: 




Light red amorphous solid; yield: 12 %; m. p. 166 
- 168 °C; 1H NMR (400 MHz, DMSO-d6): δ 7.75 
(s, 1H), 7.56 (d, J = 8.7 Hz, 2H), 6.93 (d, J = 8.7 
Hz, 2H), 6.68 (s, 2H), 3.76 (s, 3H); 13C NMR (100 
MHz, DMSO-d6): δ 161.5, 158.5, 138.8, 126.0, 
125.9, 124.9, 114.0, 55.1; EIMS (m/z): 190 (88), 
161 (6), 134 (100), 119 (8), 107 (3), 91 (16), 81 
(3), 77 (11), 63 (3), 51 (8); HREIMS: C10H10N2O2, 




Light yellow amorphous solid; yield: 10 %; m. p. 
174 - 176 °C; 1H NMR (400 MHz, DMSO-d6): δ 
8.15 (d, J = 7.2 Hz, 2H), 7.92 (s, 1H), 7.83-7.68 
(m, 3H), 7.62 (t, J = 7.8 Hz, 2H), 7.29 (d, J = 8.6 
Hz, 2H), 6.78 (s, 2H); 13C NMR (100 MHz, 
DMSO-d6): δ 164.7, 161.7, 149.6, 138.4, 134.2, 
130.0, 129.9, 129.1, 129.0, 127.4, 125.8, 122.1; 
EIMS (m/z): 280 (27), 105 (100), 77 (43), 51 (12); 





Yellow amorphous solid; yield: 30 %; m. p. 182 - 
184 °C; 1H NMR (400 MHz, DMSO-d6): δ 7.94 (s, 
1H), 7.59-7.53 (m, 4H), 6.79 (s, 2H); 13C NMR 
(100 MHz, DMSO-d6): δ 161.7, 138.1, 131.5, 
131.4, 127.9, 126.7, 120.0; EIMS (m/z): 240 (84) 
Carballo et al 
Trop J Pharm Res, August 2017; 16(8): 1954  
 
238 (85), 212 (4), 211 (4), 210 (4), 209 (4), 184 
(99), 182 (100), 157 (6) 131 (9) 129 (3), 104 (9), 
103 (26), 102 (27), 89 (47), 76 (20), 63 (18), 50 





White amorphous solid; yield: 30 %; m. p. 189 - 
191 °C; 1H NMR (400 MHz, DMSO-d6): δ 7.86 (s, 
1H), 7.67 (dd, J = 8.1, 5.8 Hz, 2H), 7.20 (t, J = 
8.7 2H), 6.76 (s, 2H); 13C NMR (100 MHz, 
DMSO-d6): δ 161.7, 161.3 (d, J = 244.5 Hz, CF), 
138.2, 128.6 (d, J = 3.2 Hz, CF), 127.1, 126.6 (d, 
J = 8.1 Hz, CF), 115.5 (d, J = 21.6 Hz, CF); EIMS 
(m/z): 178 (69) 149 (6), 122 (100), 107 (22), 95 
(12), 75 (10), 69 (1), 57 (5), 50 (4); HREIMS: 




Light red amorphous solid; yield: 36 %; m. p. 187 
- 189 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.23 
(d, J = 8.8 Hz, 2H), 8.18 (s, 1H), 7.87 (d, J = 8.8 
Hz, 2H), 6.95 (s, 2H); 13C NMR (100 MHz, 
DMSO-d6): δ 162.0, 146.0, 138.7, 137.6, 130.5, 
125.4, 124.1; EIMS (m/z): 205 (100) 175 (4), 149 
(53), 119 (5), 103 (22), 89 (13), 76 (8), 63 (8), 50 
(4); HREIMS: C10H7N3O3, calcd.: 205.0487, 
found: 205.0423. 
 
In vitro giardicidal and trichomonicidal assay 
 
The results for in vitro giardicidal and 
trichomonicidal activities of synthesized 





The physicochemical descriptors obtained for 
each synthesized 2-amino-4-(p-substituted 





was obtained as light yellow amorphous solid. 
The HREIMS gave an ion peak at m/z 280.0847 
corresponding to the molecular formula 
C16H12N2O3 (calcd 280.0848), which was in good 
agreement with 13C NMR and DEPT data. The 
1H NMR spectrum revealed the presence of two 
sharp singlets at  6.74 and 7.87, attributed to 
the protons of amino group and H-5, 
respectively. Moreover, three doublets ( 7.29, 
7.73, 8.15) and two triplets ( 7.62 and 7.76; J = 
7.6 Hz each) were present in the aromatic 
region. The two first doublets showed the same 
coupling constant value (8.6 Hz); this splitting 
pattern corresponds to p-disubstituted aromatic 
ring, and according to the literature the signals 
were assigned to H8,10 and H7,11, respectively 
[13]. The last one doublet ( 8.15, J = 8.0 Hz) as 
well as the triplets at  7.62 (J = 8.0 Hz) and 7.76 
(J = 8.0 Hz) indicates the presence of the 
monosubstituted aromatic ring. These signals 
were assigned to positions H2’,6’; H3’,5’ and H4’, 
respectively. The 13C NMR spectrum and DEPT 
experiments confirmed the presence of sixteen 
carbon atoms, corresponding to six quaternary 
carbons and ten methines. In the same fashion, 
the structures of the other synthetized 
compounds were confirmed using NMR and EM 
data. 
Table 1: Antiprotozoal activity and physicochemical descriptors of synthesized 2-amino-4-(p-
substitutedphenyl) oxazoles 
 
Comp. aIC50 (µM ± SDb) Polarizability CLogP CMRc MWd NAe 
 G. lamblia T. vaginalis   (cm3/mol)   
3a 8.84 ± 1.04 6.61 ± 1.27 53.65 1.592 46.25 160 20 
3b 9.07 ± 1.04 6.57 ± 1.17 55.13 2.091 52.15 174 23 
3c 9.02 ± 1.04 6.35 ± 1.17 54.23 1.616 53.50 190 24 
3d 1.17 ± 1.15 4.94 ± 1.05 63.08 3.174 77.58 280 33 
3e 5.67 ± 1.13 1.89 ± 1.07 55.16 2.480 53.94 238 21 
3f 30.15 ± 1.14 10.33 ± 1.13 54.02 1.760 46.65 178 21 
3g 3.55 ± 1.12 6.60 ± 1.20 55.96 1.388 - 205 23 
MTZd 1.40 ± 0.07 0.72 ± 0.03      
a50% inhibitory concentration, bstandard deviation, ccalculated molar refractivity, dmolecular weigth, 
enumber of atoms, dmetronidazole (positive control) 
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Considering the fact that thiazole and 1,3-
oxazole are molecular scaffolds containing 
divalent bioisosteres (oxygen and sulfur) [14], 
and that 2-amino-4-(p-phenyl substituted) 
thiazoles exhibit antigiardiasic activity [13], the 
synthesized 2-amino-4-(p-phenylsubstituted)-
oxazoles were tested against the 
amitochondriate protozoa G. lamblia and T. 
vaginalis. 
 
Six of the seven assayed compounds exhibited 
antiprotozoal activity against both protozoa at 
IC50 below than 10 µM. 
 
Small molecules are normally tested for in vitro 
hit identification at concentrations of 1 - 50 µM 
[16]; any compound exhibiting activity at a 
concentration lower than 25µM is considered as 
having significant activity [17]. Using this 
criterion, the results show both protozoa to be 
susceptible to almost all the synthesized 
oxazoles at concentrations below 10 µM. Versus 
T. vaginalis, 2-amino-4-(p-bromophenyl)-oxazole 
(3e) exhibited an IC50 of 1.89 µM (0.45 µg/mL). 
When challenged against G. lamblia, 2-amino-4-
(p-benzoyloxyphenyl)oxazole (3d)), a new 
oxazole, inhibited growth at 1.17 µM (0.33 
µg/mL) while 2-amino-4-(p-nitrophenyl)-oxazole 
(3g) did so at 3.55 µM (0.73 µg/mL). Due to their 
IC50 <1 µg/mL, these compounds can be 
considered as hits [18].  Unexpectedly, the 
compound 3d exhibited antigiardial activity 
higher than that of metronidazole, the most 
common drug used treating giardiasis. In a 
previous QSAR study, we prepared 2-amino-4-
(p-phenylsubstituted)thiazoles that had 
antigiardiasic activity (IC50) ranging from 20.3 - 
108.3 µM [13]. In this study, it was determined 
that EM2 (polarizability) and Hypnotic-80 
(lipophilicity) were the two most significant 
descriptors of a synthesized thiazoles’ 
antigiardial activity [13]. The Hypnotic-80 
descriptor correlates to compounds with 162 - 
360 g/mol molecular weight, number of atoms 
from 20 - 45, a calculated Log P ranging from 0.5 
to 3.99, and a calculated molar refractivity (CMR) 
of 43 - 97cm3/mol [19]. The oxazoles synthesized 
in the present study exhibited a higher 
antiprotozoal activity than previously prepared 
thiazoles, some being up to twelve times more 
active [13]. Their calculated EM2 and Hypnotic-
80 values confirmed this activity (Table 1). And, 
as expected, all these oxazoles met the criteria 
for the Hypnotic-80 descriptor for Log P (1.388 - 
3.174) and molar refractivity (46.25 - 77.58 
cm3/mol). Of note this that the oxazoles with the 
highest activity against G. lamblia and T. 
vaginalis also had the highest values for 
polarizability, CLogP, CMR, molecular weight 
and number of atoms. 
 
To the best of our best knowledge, this is the first 
time that 2-amino-4-(p-
benzoyloxyphenyl)oxazole (3d), the most active 





Bioisosteric replacement of sulfur by oxygen in 
the heterocyclic moiety is highly significant for 
antiprotozoal activity since the synthesized 
oxazoles exhibited antigiardial activity up to 12-
fold greater than that of related thiazoles. The in 
vitro antigiardial activity of the novel 2-amino-4-
(p-benzoyloxyphenyl)oxazole is higher than that 
exhibited by the commercial drug, metronidazole. 
Building on these promising preliminary results 
will require developing a library of 2-amino-4-(p-
substituted phenyl) oxazoles for analysis in 
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